Stanford University
Showing 161-170 of 634 Results
-
Irmina A. Elliott, MD
Clinical Assistant Professor, Cardiothoracic Surgery
BioDr. Elliott is a thoracic surgeon and clinical assistant professor in the Department of Cardiothoracic Surgery at Stanford University School of Medicine. She provides the complete spectrum of surgical care for lung cancer, esophageal cancer, mediastinal tumors, and more through the Stanford Health Care Thoracic Cancer Program. She specializes in minimally invasive, including robotic, approaches to thoracic surgery.
Dr. Elliott received fellowship training from Stanford University. She completed her residency at UCLA Medical Center.
Her research has received support from the National Institutes of Health. She has investigated cancer cell response to replication stress, outcomes in patients undergoing hyperthermic intrathoracic chemotherapy (HITHOC) for mesothelioma, complications after esophageal surgery, lymph node involvement in patients with carcinoid tumors of the lung, advanced techniques in robotic surgery, and other topics.
She has authored articles that have appeared in the Proceedings of the National Academy of Sciences (PNAS), Annals of Thoracic Surgery, JAMA Surgery, and other peer-reviewed publications. She also has contributed to textbooks including the content on social disparities in lung cancer for the book Social Disparities in Thoracic Surgery.
Dr. Elliott has made presentations to her peers at meetings of the American Association for Thoracic Surgery, Society of Surgical Oncology, Western Thoracic Surgical Association, and other organizations. Presentations focused on surgical treatment of patients with carcinoid tumor of the lung, improvement of mesothelioma patient survival, complications of esophageal surgery, novel targets for cancer treatment, and more. -
Edgar Engleman
Professor of Pathology and of Medicine (Immunology and Rheumatology)
Current Research and Scholarly InterestsDendritic cells, macrophages, NK cells and T cells; functional proteins and genes; immunotherapeutic approaches to cancer, autoimmune disease, neurodegenerative disease and metabolic disease.
-
Alice C. Fan
Associate Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsDr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.
-
C. Garrison Fathman
Professor of Medicine (Immunology and Rheumatology), Emeritus
Current Research and Scholarly InterestsMy lab of molecular and cellular immunology is interested in research in the general field of T cell activation and autoimmunity. We have identified and characterized a gene (GRAIL) that seems to control regulatory T cell (Treg) responsiveness by inhibiting the Treg IL-2 receptor desensitization. We have characterized a gene (Deaf1) that plays a major role in peripheral tolerance in T1D. Using PBC gene expression, we have provisionally identified a signature of risk and progression in T1D.
-
David Feldman
Professor of Medicine (Endocrinology, Gerontology and Metabolism), Emeritus
Current Research and Scholarly InterestsStudies of the role of the vitamin D receptor in the action of 1,25-dihydroxyvitamin D, the active vitamin D hormone. Current efforts are evaluating the vitamin D receptor in breast and prostate cancer, osteoporosis and rickets.
-
Marcus Feldman
Burnet C. and Mildred Finley Wohlford Professor
Current Research and Scholarly InterestsHuman genetic and cultural evolution, mathematical biology, demography of China
-
Dean W. Felsher
Professor of Medicine (Oncology) and of Pathology
Current Research and Scholarly InterestsMy laboratory studies the molecular basis of cancer with a focus on understanding when cancer can be reversed through targeted oncogene inactivation.
